Monoclonal Antibodies Targeting Amyloid ...

The incidence and prevalence of cutaneous melanoma in the US and worldwide have increased over the last 5 decades. JAMA Review Author John Kirkwood, MD, discusses the epidemiology, risk factors, treatment, and prevention of melanoma with JAMA Deputy Editor Kristin Walter, MD, MS. ... Show More

Hemorrhoidal disease, pathology of the tissue lining the anal canal, affects approximately 10 million individuals in the US. Author Jean H. Ashburn, MD, of Wake Forest University School of Medicine and JAMA Senior Editor Karen E. Lasser, MD, MPH, discuss the current evidence on t ... Show More

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS ra ... Show More

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ... Show More

Amanda Grant Smith is a geriatric psychiatrist with decades of experience treating patients with dementia and Alzheimer's disease. In this episode, Amanda shares how she developed a passion for geriatric psychiatry as a means to support dementia patients. She explains how to reco ... Show More

Beau Ances (Washington University in St Louis, MO, USA) discusses recent research on amyloid biomarkers in people with genetic forms of Alzheimer’s disease; his Article is published in the January issue of The Lancet Neurology.  

Alzheimer’s disease is a devastating neurodegenerative condition that affects the entire family. As psychiatrists and psychologists, we often support these patients and their families throughout this entire disease process. With the recent and controversial FDA approval of aducan ... Show More

Following National Alzheimer’s Disease Awareness Month, the CDC shares what physicians and patients need to know about the disease. Lisa McGuire, PhD, lead epidemiologist at the CDC, discusses the importance of catching Alzheimer’s early, its risk factors and barriers to make Alz ... Show More

Do you know all there is to know beyond amyloid and tau in Alzheimer's disease? Credit available for this activity expires: 02/15/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000023?ecd=bdc_podcast_libsyn_mscpedu 

You are not powerless in the face of this staggeringly common disease. This episode features audio from Pesticides (DDT) and Alzheimer’s Disease, How to Prevent Alzheimer’s with Diet, and Reducing Glycotoxin Intake to Prevent Alzheimer’s. Visit the video pages for all sources and ... Show More

In this Medical News podcast, Rita Rubin interviews retired neurologist Daniel Gibbs, MD, about his efforts to lessen the stigma surrounding Alzheimer disease, which he was diagnosed with 5 years ago. Related Content: Neurologist Faces His Alzheimer Diagnosis Determined to Lessen ... Show More

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Dena Dubal is a physician-scientist and professor of neurology at UCSF whose work focuses on mechanisms of longevity and brain resilience. In this e ... Show More

A study yet to be peer-reviewed has assessed the evidence on treating COVID-19 with antibody infusions—particularly monoclonal antibodies. It has found that in the early days of the pandemic doses were too high—but things are different with Omicron and its variants, because the a ... Show More